qRT-PCR of RANKL, OPG and TSG6 mRNA in colonic snips showed increased expression over the course of infection in wildtype mice but decreased expression in IL10-KO mice. Immunofluorescence staining of ...

Amneal announced FDA acceptance of its Biologics License Application (BLA) for two proposed denosumab biosimilars ...

长期使用糖皮质激素会对骨骼健康产生显著影响，其中糖皮质激素诱导的骨质疏松症（GIOP）是最为常见的后果。此前研究表明，苍术内酯 I（Atractylenolide I，Atr I）具有抗炎、抗氧化和抗肿瘤特性，然而其对破骨细胞生成以及 GIOP 的具体作用仍不明确。在本研究中，体外实验结果显示，Atr I 以剂量依赖的方式抑制核因子 κB 受体活化因子配体（RANKL）刺激的破骨细胞分化，破坏成熟 ...

7×24小时香港交易所－R（80388）股票快讯，包括最近香港交易所－R（80388）股票市场行情资讯和影响股票涨跌的国际与经济时事。今日香港交易所－R股票最新消息与行情走势尽在掌握。 快手-W(01024)10月30日斥资1197.42万港元回购25.9万股 智通财经APP讯，快手-W(01024)发布公告，于2024年10月30日斥资1197.42万港元回购股份25.9万股，每股回购... 提 ...

2018.02.070. Epub 2018 Feb 23. PMID: 29573916. 17. Zimmerman SM‡, Heard-Lipsmeyer ME, Dimori M, Thostenson JD, Mannen EM, O’Brien CA, Morello R. “Loss of RANKL in osteocytes dramatically increases ...

First approved in 2010, RANK ligand (RANKL) inhibitor Prolia remains an important drug for Amgen. The company recorded sales of $3.25 billion for the drug last year, two thirds from the US market.

On March 3, 2025, the FDA approved Celltrion’s denosumab biosimilars, STOBOCLO® (denosumab-bmwo; 60 mg/mL injection) and OSENVELT® (denosumab-bmwo; ...